HPV VLP Vaccine with Composite Adjuvant
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HPV vaccines primarily induce humoral immune responses and require multiple injections, falling short in eliciting long-lasting protective immunity and reducing the number of doses needed.
Innovation Solution
Pharmaceutical compositions comprising HPV virus-like particles (VLPs) adsorbed to an aluminum adjuvant combined with an ISCOM-type adjuvant, which includes saponin, cholesterol, and phospholipid, to enhance both humoral and cellular immune responses, potentially reducing the number of vaccine injections required.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If HPV vaccines use aluminum adjuvant alone, then humoral immune response is induced, but the number of injections required remains high and long-lasting protective immunity is not achieved
Solution Approach 1:
The patent combines aluminum adjuvant with ISCOM-type adjuvant (comprising saponin, cholesterol, and phospholipid) to create a composite adjuvant system. This composite approach leverages the complementary immunomodulatory properties of both adjuvants to enhance both humoral and cellular immune responses, thereby achieving long-lasting protective immunity with fewer injections
Solution Approach 2:
The patent merges two different adjuvant systems (aluminum-based and ISCOM-type) into a single vaccine formulation. This combination allows the vaccine to simultaneously stimulate multiple immune pathways, improving overall immunogenicity and reducing the number of doses needed to achieve durable protection
2Reliability
If HPV vaccines require multiple injections, then adequate immune response is achieved, but productivity and convenience are reduced
Solution Approach 1:
The composite adjuvant system enhances the immunogenicity of each individual dose, allowing adequate immune response to be achieved with fewer administrations. This improves vaccine administration efficiency while maintaining immune response adequacy
Solution Approach 2:
The patent modifies the adjuvant composition parameters by incorporating ISCOM-type adjuvant components (saponin, cholesterol, phospholipid) in specific ratios with aluminum adjuvant. This parameter optimization enables reduced dosing frequency while maintaining adequate immune response
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of HPV VLPs with aluminum and ISCOM-type adjuvants induces higher antibody titers and more stable vaccine formulations, potentially achieving long-lasting protective immunity with fewer injections.
Implementation Method 1
HPV virus-like particles (VLPs) adsorbed to an aluminum adjuvant
Implementation Method 2
an ISCOM-type adjuvant, which includes saponin, cholesterol, and phospholipid
Data Source
AI summary
The present invention relates to pharmaceutical compositions comprising virus-like particles (VLPs) of HPV, said VLPs adsorbed to an aluminum adjuvant, and an ISCOM-type adjuvant comprising a saponin, cholesterol, and a phospholipid. In preferred embodiments, the aluminum adjuvant comprises amorphous aluminum hydroxyphosphate sulfate. Another aspect of the invention provides multi-dose HPV vaccine formulations comprising HPV VLPs and an antimicrobial preservative selected from the group consisting of: m-cresol, phenol and benzyl alcohol. Also provided are methods of using the disclosed pharmaceutical compositions and formulations to induce an immune response against HPV in a human patient and to prevent HPV infection.